---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-026193"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:40:45.204063+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q1 revenue down 16% to $12.8M; net income falls to $0.5M

## Summary
- Revenue $12.8M vs $15.2M YoY, a decrease of 16.0%.
- Operating income $0.6M vs $1.5M; net income $0.5M ($0.02 basic EPS) vs $1.0M ($0.04 basic EPS).
- Diluted EPS $0.02 vs $0.03 in the prior-year quarter.
- Two largest customers in Contract Manufacturing Segment accounted for ~91% of revenue, consistent with YoY.
- Co-CEOs cite pandemic-related safety stock and consumer demand in prior year as cause for revenue decline.

## SEC filing metadata
- accession: 0001437749-21-026193
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774921026193/0001437749-21-026193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774921026193/inbp20211109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-026193
- JSON: https://secwatch.observer/filing/0001437749-21-026193.json
- Plain text: https://secwatch.observer/filing/0001437749-21-026193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.